Minghua Chen

Minghua Chen

Auto-generated profile, based on publicly available information

Minghua Chen

Department of Anesthesiology, Third Xiangya Hospital, Central South University, Changsha, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2022 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
YZYoujie Zeng
Youjie Zeng
SCSi Cao
Si Cao
MCMinghua Chen
Minghua Chen
Background: Increasing evidence has suggested an association between carotid atherosclerosis (CAS) and periodontitis (PD); however, the mechanisms have not been fully understood. This study aims to investigate the shared genes and molecular mechanisms underlying the co-pathogenesis of CAS and PD. Methods: Gene Expression Omnibus (GEO) datasets GSE100927 and GSE10334 were downloaded, and differentially expressed genes (DEGs) shared by both datasets were identified. The functional enrichment analysis of these overlapping DEGs was then conducted. A protein-protein interaction (PPI) network was created using the STRING database and Cytoscape software, and PPI key genes were identified using the cytoHubba plugin. Then, weighted gene co-expression network analysis (WGCNA) was performed on GSE100927 and GSE10334, and the gene modules most correlated with CAS and PD were identified as key modules. The genes in key modules overlapping with PPI key genes were determined to be the key crosstalk genes. Subsequently, the key crosstalk genes were validated in three independent external datasets (GSE43292 [CAS microarray dataset], GSE16134 [PD microarray dataset], and GSE28829 [CAS microarray dataset]). In addition, the immune cell patterns of PD and CAS were evaluated by single-sample gene set enrichment analysis (ssGSEA), and the correlation of key crosstalk genes with each immune cell was calculated. Finally, we investigated the transcription factors (TFs) that regulate key crosstalk genes using NetworkAnalyst 3.0 platform. Results: 355 overlapping DEGs of CAS and PD were identified. Functional enrichment analysis highlighted the vital role of immune and inflammatory pathways in CAS and PD. The PPI network was constructed, and eight PPI key genes were identified by cytoHubba, including CD4, FCGR2A, IL1B, ITGAM, ITGAX, LCK, PTPRC, and TNF. By WGCNA, the turquoise module was identified as the most correlated module with CAS, and the blue module was identified as the most correlated module with PD. Ultimately, ITGAM and LCK were identified as key crosstalk genes as they appeared both in key modules and PPI key genes. Expression levels of ITGAM and LCK were significantly elevated in the case groups of the test datasets (GSE100927 and GSE10334) and validation datasets (GSE43292, GSE16134, and GSE28829). In addition, the expression of multiple immune cells was significantly elevated in PD and CAS compared to controls, and the two key crosstalk genes were both significantly associated with CD4 T cells. Finally, SPI1 was identified as a potential key TF, which regulates the two key crosstalk genes. Conclusion: This study identified the key crosstalk genes and TF in PD and CAS, which provides new insights for further studies on the co-morbidity mechanisms of CAS and PD from an immune and inflammatory perspective.

7 July 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
CFChao Fang
Chao Fang
WOWen Ouyang
Wen Ouyang
YZYoujie Zeng
Youjie Zeng
QPQi Pei
Qi Pei
YXYuhao Xia
Yuhao Xia
MCMinghua Chen
Minghua Chen
Background: Dexmedetomidine is a commonly used clinical sedative; however, the drug response varies among individuals. Thus, the purpose of this study was to explore the association between dexmedetomidine response and gene polymorphisms related to drug-metabolizing enzymes and drug response (CYP2A6, UGT2B10, UGT1A4, ADRA2A, ADRA2B, ADRA2C, GABRA1, GABRB2, and GLRA1).Methods: This study was a prospective cohort study. A total of 194 female patients aged 18–60 years, American Society of Anesthesiologists (ASA) score I-II, who underwent laparoscopy at the Third Xiangya Hospital of Central South University, were included. The sedative effect was assessed every 2 min using the Ramsay score, and the patient’s heart rate decrease within 20 min was recorded. Peripheral blood was collected from each participant to identify genetic variants in the candidate genes of metabolic and drug effects using the Sequenom MassARRAY® platform. Furthermore, additional peripheral blood samples were collected from the first 99 participants at multiple time points after dexmedetomidine infusion to perform dexmedetomidine pharmacokinetic analysis by Phoenix® WinNonlin 7.0 software.Results: Carriers of the minor allele (C) of CYP2A6 rs28399433 had lower metabolic enzyme efficiency and higher plasma concentrations of dexmedetomidine. In addition, the participants were divided into dexmedetomidine sensitive or dexmedetomidine tolerant groups based on whether they had a Ramsay score of at least four within 20 min, and CYP2A6 rs28399433 was identified to have a significant influence on the dexmedetomidine sedation sensitivity by logistic regression with Plink software [p = 0.003, OR (95% CI): 0.27 (0.11–0.65)]. C allele carriers were more sensitive to the sedative effects of dexmedetomidine than A allele carriers. GABRA2 rs279847 polymorphism was significantly associated with the degree of the heart rate decrease. In particular, individuals with the GG genotype had a 4-fold higher risk of heart rate abnormality than carriers of the T allele (OR = 4.32, 95% CI: 1.96–9.50, p = 0.00027).Conclusion:CYP2A6 rs28399433 polymorphism affects the metabolic rate of dexmedetomidine and is associated with susceptibility to the sedative effects of dexmedetomidine; GABRA2 rs279847 polymorphism is significantly associated with the degree of the heart rate decrease.

15 June 2022 in Frontiers in Neurology
Verified
Journal Article
Open access
SCSi Cao
Si Cao
YZYoujie Zeng
Youjie Zeng
MCMinghua Chen
Minghua Chen
WOWen Ouyang
Wen Ouyang
Background: Stroke is the leading cause of death and disability worldwide, with ischemic stroke (IS) being the most prevalent type. Circular RNAs (circRNAs) are involved in the pathological process of IS and are promising biomarkers for the diagnosis of IS. However, studies focusing on circRNAs acting as microRNAs (miRNAs) sponges in regulating mRNA expression are currently scarce. Methods: In this study, expression profiles of circRNAs (GSE195442), miRNAs (GSE117064), and mRNAs (GSE58294) from the Gene Expression Omnibus (GEO) database were analyzed. Differentially expressed circRNAs (DEcircRNAs), differentially expressed miRNAs (DEmiRNAs), and differentially expressed mRNAs (DEmRNAs) were identified by R software. The target miRNAs and target genes were predicted by several bioinformatics methods. Then, we performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of the DEmRNAs. Subsequently, the protein-protein interaction (PPI) network and the competing endogenous RNA (ceRNA) regulatory network were visualized by Cytoscape software. Finally, we further constructed an immune-related circRNA-miRNA-mRNA regulatory sub-network in IS. Results: A total of 35 DEcircRNAs, 141 DEmiRNAs, and 356 DEmRNAs were identified. By comprehensive analysis of bioinformatics methods, we constructed a circRNA-miRNA-mRNA regulatory network, including 15 DEcircRNAs, eight DEmiRNAs, and 39 DEmRNAs. FGF9 was identified as an immune-related hub gene. Immune cell analysis indicated a significantly higher level of neutrophils in IS, and the expression of FGF9 was significantly negatively correlated with the level of neutrophils. Eventually, miR-767-5p was predicted as the upstream molecules of FGF9, and circ_0127785 and circ_0075008 were predicted as the upstream circRNAs of miR-767-5p. Conclusion: Our study provides novel insights into the molecular mechanisms governing the progression of IS from the perspective of immune-related ceRNA networks.

30 September 2024 in Brain and Behavior
Verified
Journal Article
Open access
SCSi Cao
Si Cao
HSHan Su
Han Su
XZXiaoyi Zhang
Xiaoyi Zhang
CFchao fang
chao fang
NWNa-Yi Yuan Wu
Na-Yi Yuan Wu
MCMinghua Chen
Minghua Chen
Background: Observational studies have suggested that obsessive–compulsive disorder (OCD) may be associated with Alzheimer's disease (AD). However, whether OCD is a causal risk factor for AD remains unclear. This study aimed to assess the causal effect of OCD on AD risk by performing a two‐sample Mendelian randomization (MR) analysis.Methods: Genome‐wide association summary statistics were obtained for OCD, comprising 2688 cases and 7037 controls, as well as for AD, including 21,982 cases and 41,944 controls from Kunkle et al.’s study, and 39,918 cases and 358,140 controls from Wightman et al.’s study. On the basis of two diverse thresholds, OCD‐associated genetic variants were screened as instrumental variables (IVs) for subsequent MR analyses. Inverse variance weighed was the primary MR method. MR‐Egger, weighted median, and weighted mode were used as supplementary MR methods. Various sensitivity tests assessed the reliability of MR results.Results: On the basis of strict IV selecting thresholds, inverse‐variance weighted (IVW) identified significant causal associations between genetic liability to OCD and increased risk of AD in two different sources ((i) Kunkle et al.: odds ratio [OR] = 1.070, 95% confidence interval [CI]: 1.015–1.127, p = 0.012; (ii) Wightman et al. 0.012; (iii) Wightman et al.: OR = 1.051, 95% CI: 1.014–1.090, p = 0.007). Three other supplementary MR methods yielded similar results to IVWs (OR > 1). Furthermore, all results were replicated in MR analyses based on lenient IV selecting thresholds. The sensitivity tests indicated that MR results were stable and not affected by significant horizontal pleiotropy.Conclusions: This comprehensive MR study suggests that genetic liability to OCD is a causal risk factor for AD. Early intervention in patients with OCD may be beneficial in preventing future AD progression.